Pfizer could haul in $3.5B in 2021 from COVID-19 vaccine: analyst

Analysts at SVB Leerink took a crack at answering those questions in a note sent to investors Wednesday. Assuming an 80% chance of success for Pfizer’s coronavirus vaccine, they said, the product will peak at sales of $3.5 billion next year before flattening out at about $1.4 billion a year after that.